Jianwei W Shen

US Patent:

20100040537, Feb 18, 2010

Filed:

Jul 8, 2009

Appl. No.:

12/499646

Inventors:

Charles W. Hutchins - Green Oaks IL, US
Rong-rong Zhu - Southborough MA, US
Jianwei Shen - Lake Bluff IL, US
Maria C. Harris - Shrewsbury MA, US
Eileen Belanger - Northbridge MA, US
Anwar Murtaza - Westborough MA, US
Edit Tarcsa - Westborough MA, US
William B. Stine - Shrewsbury MA, US
Chung-ming Hsieh - Newton MA, US

Assignee:

ABBOTT LABORATORIES - Abbott Park IL

International Classification:

A61K 39/395
C07K 16/00
C07K 19/00
C07H 21/04
C12N 15/63
C12N 1/21
C12N 1/11
C12N 5/10
C12N 1/15
C12P 21/00
A61K 49/00
A61K 51/00
A61P 29/00
A61P 35/00
A61P 19/02
A61P 3/10
A61P 7/00
A61P 3/12
A61P 15/00
A61P 1/00
A61P 27/02
A61K 38/20

US Classification:

424 111, 5303871, 5303873, 5303911, 5303913, 5303917, 536 2353, 4353201, 4352528, 4352581, 435325, 43525411, 435419, 435349, 435348, 435358, 435365, 4352542, 43525421, 435 691, 4241391, 424 91, 424 852

Abstract:

The present invention encompasses prostaglandin E(PGE) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin Eand neutralize prostaglandin Eactivity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin Eand for inhibiting prostaglandin Eactivity, e.g., in a human subject suffering from a disorder in which prostaglandin Eactivity is detrimental.

US Patent:

20140186377, Jul 3, 2014

Filed:

Nov 26, 2013

Appl. No.:

14/090664

Inventors:

- North Chicago IL, US
Charles W. Hutchins - Green Oaks IL, US
Rong-Rong Zhu - Southborough MA, US
Jianwei Shen - Lake Bluff IL, US
Maria C. Harris - Shrewsbury MA, US
Eileen Belanger - Northbridge MA, US
Tariq Ghayur - Holliston MA, US
Paul R. Hinton - Sunnyvale CA, US
Veronica M. Juan - Menlo CA, US
John Mankovich - Andover MA, US
Junjian Liu - Shrewsbury MA, US

Assignee:

AbbVie, Inc. - North Chicago IL

International Classification:

C07K 16/18
A61K 31/573
A61K 31/405
A61K 39/395

US Classification:

4241751, 5303898, 5303873, 5303889, 5303913, 5303917, 435188, 536 2353, 4353201, 43525233, 435345, 435419, 43525411, 4352542, 43525421, 435 696, 435 792

Abstract:

The present invention encompasses prostaglandin E(PGE) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin Eand neutralize prostaglandin Eactivity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin Eand for inhibiting prostaglandin Eactivity, e.g., in a human subject suffering from a disorder in which prostaglandin Eactivity is detrimental.